Clinical trial NCT04638660: Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Official title: Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dim Light Vision Disturbances
Keywords: Nyxol, Night Vision Disturbances, Glare, Halos, Starbursts
Lead sponsor: Ocuphire Pharma, Inc.
Sponsor class: INDUSTRY
First posted: 2020-11-20
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: All subjects will be randomized into the study in a 1:1 ratio to one of the treatment arms (Nyxol or placebo), with a stratification by light/dark irides.
Primary purpose: TREATMENT

Brief summary: The objectives of this study are:

* To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD)
* To evaluate efficacy of Nyxol to improve visual performance
* To evaluate the safety of Nyxol

Detailed description: Placebo-controlled, double-masked, multiple-dose, Phase 3 study in approximately 160 randomized subjects with DLD (approximately 136 that are evaluable for efficacy), evaluating safety and efficacy of Nyxol in subjects with DLD following administration of Nyxol once daily (QD) at or near bedtime (at 8PM to 10PM) in both eyes (OU) for 14 days.

Following the successful completion of screening, each subject will be stratified by iris color (light/dark irides) and will then be randomized to treatment (masked) 1:1, Nyxol or placebo (vehicle).

Treatment (Nyxol or placebo) will be administered in both eyes (OU) by the subjects at or near bedtime each day.

At the first visit subjects will be screened for study eligibility.

Treatment visits will occur 2 times: Day 8 (+1 day)/Visit 2 and Day 15 (+1 day)/Visit 3. mLCVA evaluations shall be performed on each of these days.

A follow-up visit (Visit 4) phone call will occur 1 to 3 days after Visit 3.

At select sites OPD Scan measurements will be made using wavefront abhermettry.

Eligibility criteria: Inclusion Criteria:

1. Males or females ≥ 18 years of age
2. Subject-reported DLD (likely subjects with a history of multifocal IOLs, post-laser-assisted in situ keratomileusis \[LASIK\], corneal scars, and keratoconus)
3. Ability to comply with all protocol-mandated procedures independently and to attend all
4. Otherwise healthy and well-controlled subjects
5. Able and willing to give written consent to participate in this study
6. Able to self-administer study medication
7. PD ≥ 6 mm under mesopic conditions (prior to illumination) in at least one eye
8. ≤ 20 (20/100 Snellen or worse) ETDRS letters in mLCVA score

Exclusion Criteria:

Ophthalmic:

1. Prior history of dry eye diagnosis, taking prescription drops for dry eye, or taking artificial tear drops occasionally for dry eye
2. Prior history of fluctuating vision
3. Clinically significant ocular disease as deemed by the Investigator that might interfere with the study
4. Known hypersensitivity to any topical alpha-adrenoceptor antagonists
5. Known allergy or contraindication to any component of the vehicle formulation
6. History of cauterization of the punctum or punctal plug (silicone or collagen) insertion or removal
7. Ocular trauma, ocular surgery (e.g., IOLs) or laser procedure (e.g., LASIK, photorefractive keratectomy \[PRK\]) within 6 months prior to screening
8. Use of any topical prescription or over-the-counter (OTC) ophthalmic medications of any kind within 7 days of screening
9. Recent or current evidence of ocular infection or inflammation in either eye. Subjects must be symptom free for at least 7 days.
10. History of diabetic retinopathy, diabetic macular edema, or dry or wet macular degeneration
11. History of any traumatic (surgical or nonsurgical) or nontraumatic condition affecting the pupil or iris
12. Unwilling or unable to discontinue use of contact lenses at screening until study completion, except for keratoconus subjects who may wear contacts up to 24 hours prior to their scheduled visits

Systemic:

1. Known hypersensitivity or contraindication to alpha- and/or beta-adrenoceptor antagonists
2. Clinically significant systemic disease that might interfere with the study
3. Initiation of treatment with or any changes to the current dosage, drug, or regimen of any systemic adrenergic or cholinergic drugs within 7 days prior to screening or during the study
4. Participation in any investigational study within 30 days prior to screening and during the conduct of the study
5. Females of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control
6. Resting HR outside the specified range (50-110 beats per minute)
7. Hypertension with resting diastolic BP \> 105 mmHg or systolic BP \> 160 mmHg

Primary outcomes:
measure: Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye
timeFrame: 8 days
Secondary outcomes:
measure: Percent of Subjects With mLCVA Improvement in Study Eye
timeFrame: up to 15 days
measure: Percent of Subjects With Photopic Low Contrast Visual Acuity (pLCVA) and mHCVA Improvement in Study Eye
timeFrame: up to 15 days
measure: Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)
timeFrame: up to 15 days
measure: Percent Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)
timeFrame: up to 15 days
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: Clinical Site 6
state: California
city: Petaluma
country: United States
facility: Clinical Site 1
state: California
city: Jacksonville
country: United States
facility: Clinical Site 3
state: Florida
city: Jacksonville
country: United States
facility: Clinical Site 18
state: Florida
city: Pittsburg
country: United States
facility: Clinical Site 13
state: Kansas
city: Edgewood
country: United States
facility: Clinical Site 20
state: Kentucky
city: Louisville
country: United States
facility: Clinical Site 14
state: Kentucky
city: Palisades Park
country: United States
facility: Clinical Site 10
state: New Jersey
city: Pennington
country: United States
facility: Clinical Site 8
state: New Jersey
city: Elizabeth City
country: United States
facility: Clinical Site 4
state: North Carolina
city: High Point
country: United States
facility: Clinical Site 22
state: North Carolina
city: High Point
country: United States
facility: Clinical Site 9
state: North Carolina
city: Fargo
country: United States
facility: Clinical Site 2
state: North Dakota
city: Warwick
country: United States
facility: Clinical Test 15
state: Rhode Island
city: Memphis
country: United States
facility: Clinical Site 11
state: Tennessee
city: San Antonio
country: United States
facility: Clinical Site 5
state: Texas
city: Ogden
country: United States
facility: Clinical Site 19
state: Utah
Study officials:
References: